Immunic Inc
IMUX
NASDAQ
Biotechnology
$16.06
USD
-0.52 (-3.14%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $225.34M
Volume 79.7K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-111.57M
TTM
-9.6%
YoY
Operating Cash Flow
$-87.72M
TTM
+2.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.7 | 6.0 | 4.3 | 7.6 | 9.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 27.1 | 26.0 | 23.3 | 33.2 | 35.3 |
Operating Income | -27.1 | -26.0 | -23.3 | -33.2 | -35.3 |
EBITDA | -27.0 | -26.0 | -23.3 | -33.2 | -35.3 |
Other Income / Expense | 0.0 | -0.0 | 3.8 | -0.1 | -0.1 |
Total Other Income / Expense | 0.3 | 0.4 | 4.0 | 0.6 | 1.2 |
Income Before Income Taxes | -26.8 | -25.6 | -19.3 | -32.6 | -34.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -26.8 | -25.6 | -19.3 | -32.6 | -34.1 |
Consolidated Net Income / Loss | -26.8 | -25.6 | -19.3 | -32.6 | -34.1 |
Net Income Attributable to Common Shareholders | -26.8 | -25.6 | -19.3 | -32.6 | -34.1 |
Basic EPS | -$2.03 | -$1.30 | -$0.99 | -$1.08 | -$0.80 |
Diluted EPS | -$2.03 | -$1.30 | -$0.99 | -$1.08 | -$0.80 |
Basic Shares Outstanding | 13.2M | 19.4M | 19.5M | 30.1M | 42.5M |
Diluted Shares Outstanding | 13.2M | 19.4M | 19.5M | 30.1M | 42.5M |